NCT03335267已完成2 期
Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Primary Efficacy
研究概览
简要总结
This is an open label study to assess the suitability of CPX-351 as first intensive therapy in elderly (age ≥60 years) patients with AML. Patients may have received prior AML treatment with non-intensive regimens, e.g. hypomethylating agents, low dose Ara C or lenolidomide, but may not have received intensive AML treatment with anthracyclines and/or cytarabine prior to enrollment on this trial. The outcome of elderly patients following intensive treatment with CPX-351 will be measured by clinical endpoints for efficacy and safety and by biological/functional response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and voluntarily give informed consent
- •Age≥60 years at the time of study treatment
- •Pathological diagnosis of AML according to WHO criteria (with >20% blasts in the peripheral blood or bone marrow) including:
- •De novo AML with normal karyotype or adverse karyotypes (including patients with karyotypic abnormalities characteristic of MDS)
- •Secondary AML: transformed from prior MDS or MPN, confirmed by bone marrow documentation of prior antecedent hematologic disorder
- •Therapy-related AML: t-AML, requires documented history of prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease
- •Performance status >50% KPS, ECOG 0-2
- •Laboratory values fulfilling the following:
- •Serum creatinine < 2.5 mg/dL
- •Serum total bilirubin < 2.5 mg/dL,
- •Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN
- •Patients with elevated liver enzymes and serum creatinine values secondary to AML are eligible after discussion with PI
- •Cardiac ejection fraction ≥ 50% by echocardiography or MUGA
- •Patients with history of second malignancies in remission may be eligible if there is clinical evidence of disease stability off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible.
排除标准
- •Acute promyelocytic leukemia [t(15;17)]
- •Clinical evidence of active CNS leukemia
- •Prior intensive chemotherapy for AML with anthracycline/cytarabine-based regimens and/ or prior HSCT. Patients may have been treated with commercially available or investigational hypomethylating agents (e.g. decitabine, azacitidine, SGI-110), lenalidomide, or low-dose cytarabine (not to exceed 20 mg/m2 daily for 14 days for ≤ 6 cycles)
- •Prior treatment including HMA, systemic chemotherapy, surgery, or radiation therapy must have been completed at least 7 days before start of study treatment or after discussion with PI. Treatment with investigational agents must have been completed at least 14 days prior to study drug treatment. Hydroxyurea is permitted for control of blood counts before the start of study treatment. Toxicities associated with prior therapies must have recovered to grade 1 or less prior to start of study treatment.
- •Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).
- •Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent
- •Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging)
- •Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥72 hrs.
- •Patients with current or recent evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible
- •Known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values)
- •Hypersensitivity to cytarabine, daunorubicin or liposomal products
- •History of Wilson's disease or other copper-metabolism disorder
- •History of prior bone marrow or solid organ transplantation
研究组 & 干预措施
CPX-351 (Cytarabine:Daunorubicin) Injection
Experimental
Dosing for first induction: CPX-351
• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5
Dosing for second induction:
• CPX-351 at 100 u/m2 will be administered on days 1 and 3
Dosing for consolidation:
• CPX-351 at 65 u/m2 will be administered on days 1 and 3
干预措施: CPX-351 (Drug)
结局指标
主要结局
Primary Efficacy
时间窗: 2.5 Years
Overall survival is measured from the date of registration to death from any cause. Patients not known to have died will be censored on the date they were last known to be alive. Patients were followed for 2.5 years.
30-Day Mortality Rate
时间窗: 30 Days
Mortality rate at Day 30
次要结局
- Change in Relationship of Cognitive Function to Treatment Response and OS, Event-free Survival and Morphologic Leukemia Free State as Measured by the MOCA(Screening through 30 days post-treatment, up to 3 months post-baseline)
- Complete Response Rate (CR, CRp, CRi, and CR+CRp+CRi)(30 days post-treatment, up to 3 months post-baseline)
- Change in Relationship of Cognitive Function to Treatment Response and OS, Event-free Survival and Morphologic Leukemia Free State as Measured by the Blessed Orientation-Memory-Concentration Test(Screening through 30 days post-treatment, up to 3 months post-baseline)
- Incidence of Adverse Events(Through treatment completion, an average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeSecondary Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02286726M.D. Anderson Cancer Center56
已完成
1 期
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.Hematologic NeoplasmsNCT00389428Jazz Pharmaceuticals48
招募中
1 期
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaBlasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory High Risk Myelodysplastic SyndromeNCT03896269M.D. Anderson Cancer Center38
已完成
2 期
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years OldAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Myelodysplasia-Related ChangesSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaNCT04269213Roswell Park Cancer Institute21
终止
2 期
CPX-351 Therapy for MDS After Hypomethylating Agent FailureMyelodysplastic Syndrome (MDS)NCT03957876Case Comprehensive Cancer Center4